Topical PDE4 Inhibitor for Plaque Psoriasis Passes Muster With FDA

(MedPage Today) -- The FDA approved the topical PDE4 inhibitor roflumilast (Zoryve) for mild-to-severe plaque psoriasis, including for intertriginous areas, in patients ages 12 years and older, Arcutis Biotherapeutics announced. Roflumilast cream...
Source: MedPage Today Public Health - Category: American Health Source Type: news